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Abstract: Implementation of antibiotic stewardship is difficult in patients with sepsis because of
severity of disease. We evaluated the impact of glycopeptide discontinuation (GD) in patients with
culture negative severe sepsis or septic shock who received glycopeptides as initial empiric antibiotic
therapy at admission. We conducted a single center retrospective cohort study between January 2010
and March 2018. GD was defined as discontinuation of initial empiric glycopeptides on availability
of culture results, revealing the absence of identified pathogens. In 92 included patients, the leading
causes of sepsis were pneumonia (34.8%) and intra-abdominal infection (23.9%); 28-day mortality
and overall mortality were 14% and 21%, respectively. Glycopeptides were discontinued in 42/92
patients. After propensity score matching, baseline characteristics were not significantly different
between the GD and non-GD (GND) groups. GND was associated with development of acute kidney
injury (OR 5.54, 95% CI 1.49–20.6, P = 0.011). GD did not increase the 7-day, 14-day, and 28-day
mortality compared with GND. The length of hospital stay was shorter in the GD group than in GND
group (16.33 ± 17.11 vs. 25.05 ± 14.37, P = 0.082), though not statistically significant. GD may be safe
and reduce adverse events of prolonged antibiotic use in patients with culture negative severe sepsis
or septic shock receiving glycopeptides as initial empiric antibiotic therapy.
Keywords: glycopeptides; antimicrobial stewardship; sepsis; septic shock; propensity score
1. Introduction
International guidelines recommend the prompt use of empirical broad-spectrum antibiotics in
patients with severe sepsis or septic shock [1]. Once the pathogen is identified and its susceptibility
profile is determined, the use of empiric antibiotics should be adjusted to minimize inappropriate
exposure to broad-spectrum antimicrobial agents [2]. This strategic de-escalation (DE) reduces
the spectrum of antimicrobials by using narrow spectrum antibiotics, decreasing the number of
antimicrobials in combination therapy, and discontinuing the use of unnecessary agents [3]. A study
reported that DE therapy did not increase mortality risk in patients with severe sepsis or septic shock [4].
Another study even demonstrated improved survival in patients who received antimicrobial DE
therapy [5]. However, only a few studies deal with the impact of DE therapy in relation to specific
pathogens or specific antibiotics [6].
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Glycopeptides are effective against infections caused by Gram-positive pathogens, such as
enterococci or methicillin-resistant Staphylococcus aureus (MRSA). They are also used for empirical
antimicrobial therapy in patients with severe sepsis and septic shock when MRSA infection is
suspected [1]. Since the methicillin resistance rate of Staphylococcus aureus reached approximately 66%
in South Korea [7], most clinicians select glycopeptides as initial empiric antibiotics for patients with
severe sepsis or septic shock. However, many of them do not implement DE even when the initial
microbiologic results do not suggest MRSA infection. Such excessive and inappropriate antimicrobial
use has influenced the emergence of antimicrobial resistant organisms and increased adverse drug
events [8,9]. In clinical practice, physicians’ decisions to discontinue the use of glycopeptides depend
on the severity of a patient’s condition rather than the microbiologic results.
The absence of an identified pathogen was shown to be a risk factor for not performing antimicrobial
DE, and many studies on antimicrobial DE excluded patients with negative culture results [3]. Therefore,
it is necessary to study the impact and safety of glycopeptide discontinuation (GD) in critically ill
patients with infection when there are no identified pathogens in the initial culture data. Therefore,
in this study, we evaluated the impact of GD on the clinical outcomes in patients with severe sepsis or
septic shock who received glycopeptides as initial empiric antibiotics and had negative culture results
at admission in the emergency department.
2. Results
2.1. Study Population
Of the 1514 patients enrolled in the sepsis critical pathway program, only 111 patients with
culture negative severe sepsis or septic shock, who received glycopeptides as the initial empirical
antibiotics therapy, were eligible. Based on the exclusion criteria, an additional 19 patients were
excluded. Therefore, 92 patients were finally included in the final analysis. GD was performed in
42 patients, and GD and non-GD (GND) in 50 patients (Figure 1).
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Table 1 shows the clinical characteristics and outcomes of patients included in this study. The mean
age of patients was 61.07± 14.26; 39.13% were women and 56.52% had an MRSA risk factor at admission.
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The most common underlying comorbidity was hypertension (54.34%), followed by cancer (41.3%) and
diabetes mellitus (28.26%). The initial sequential organ failure assessment (SOFA) score (8.68 ± 2.86)
was higher than the SOFA score on day 5 (4.1 ± 4.25). Approximately two-thirds of the patients (63.04%)
were admitted to the intensive care unit (ICU) from the emergency department. Pneumonia accounted
for the largest proportion of primary focus of sepsis (34.78%). During hospitalization, acute kidney
injury (AKI) was developed in 17.39% of patients; 28-day mortality occurred in 15.22% and the overall
mortality was 22.83%.
Table 1. Clinical characteristics and outcomes of patients in the study.
Variables Total (n = 92)
Demographic
Female, no. (%) 36(39.13)
Age, years 61.07(14.26)
Body mass index, kg/m2 23.96(10.98)
Laboratory
White blood cell count per mm3 14,520(16,826)
Hematocrit, % 34.2(8.26)
Platelet per mm3 183,745(123,401.5)
Blood urea nitrogen, mg/dL 32.71(25.63)
Creatinine, mg/dL 2.31(2.38)
Total bilirubin, mg/dL 1.07(1.08)
Albumin, g/dL 3.18(0.74)
C-reactive protein, mg/L 137.58(112.75)
Lactate, mmol/L 4.12(3.18)
Comorbidities
Congestive heart failure, no. (%) 6(6.52)
Hypertension, no. (%) 50(54.34)
Pulmonary disease, no. (%) 7(7.61)
Liver disease, no. (%) 6(6.52)
Diabetes mellitus, no. (%) 26(28.26)
Renal disease, no. (%) 13(14.13)
Cancer, no. (%) 38(41.3)
Risk factor for MRSA, no. (%) 52(56.52)
Initial SOFA score 8.68(2.86)
Admission to ICU from emergency department, no. (%) 58(63.04)
SOFA score at day 5 4.1(4.25)
Primary focus of sepsis
Primary sepsis, no. (%) 19(20.65)
Pneumonia, no. (%) 32(34.78)
Intra-abdominal, no. (%) 22(23.91)
Skin and soft tissue, no. (%) 8(8.7)
Others a, no. (%) 11(11.96)
Outcomes
Acute kidney injury, no. (%) 16(17.39)
28-day mortality, no. (%) 14(15.22)
Overall mortality, no. (%) 21(22.83)
MRSA, methicillin-resistant Staphylococcus aureus; SOFA, sequential organ failure assessment; ICU, intensive care
unit. a Others include central nervous system infections, gastroenteritis, deep neck infection, and others.
2.2. Characteristics of Patients Before and After Propensity Score Matching
Before propensity score matching (PSM), GND patients had higher lactate levels (4.9± 4.18 mmol/L
vs. 3.3 ± 2.41 mmol/L, P = 0.029) and initial SOFA scores (9.36 ± 3.17 vs. 7.95 ± 2.37, P = 0.02) than GD
patients (Table 2). In addition, the percentage of patients with congestive heart failure was significantly
higher in the GND group than in the GD group (12% vs. 0%, P = 0.03). Although not statistically
significant, the white blood cell counts (11,727.14 ± 10,485.66/mm3 vs. 16,539.4 ± 21,144.89/mm3),
total bilirubin (0.91 ± 0.76 mg/dL vs. 1.22 ± 1.33 mg/dL), C-reactive protein (118.5 ± 87.18 mg/L vs.
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152.78 ± 127.66 mg/L), SOFA score on day 5 (3.5 ± 3.62 vs. 4.7 ± 4.67), and ICU admission rate (57.1%
vs. 68%) were higher in the GND group than in the GD group. Risk factors for MRSA were more
frequently observed in the GD group than in the GND group (64.3% vs. 50%).
After PSM, 21 patients remained in each group. Significant differences in baseline characteristics
disappeared between both propensity score matched groups. Comparing with patients in the GND
group, those in the GD group had numerically lower C-reactive protein levels (127.84 ± 93.94 mg/L
vs. 167.4 ± 152.37 mg/L, p = 0.339) and initial SOFA scores (8.05 ± 2.20 vs. 9.14 ± 3.73, p = 0.169).
The percentage of patients with lung disease was numerically higher in the GD group than in the GND
group. In addition, the overall distribution of the primary focus of sepsis was not significantly different
between the two groups, but the proportion of septic focus that may require empirical glycopeptides,
such as pneumonia, intra-abdominal infection, and surgical site infection was numerically higher in
the GD group (76.2% vs. 57.1%, P = 0.102, data not shown).
2.3. Outcomes
The GD group had a shorter duration of glycopeptide use than GND group (4.39 ± 1.76 days vs.
14.86 ± 6.58 days, P = < 0.001). GND was significantly associated with a likelihood of AKI development
both before matching (odds ratio (OR) 4.16, 95% confidence interval (CI) 1.49–11.6, P = 0.007) and
after matching (OR 5.54, 95% CI 1.49–20.6, P = 0.011) (Table 3). In the GD group, none of the patients
underwent hemodialysis after the use of glycopeptides, whereas three patients in the GND group
underwent hemodialysis. Although the 7-day, 14-day, and 28-day mortalities were not significantly
associated with glycopeptides DE before and after PSM, the 28-day mortality was numerically lower
in the GD group than in the GND group before matching (9.5% vs. 20%, p = 0.172) and after matching
(9.5% vs. 19.1%, p = 0.427). The length of hospital stay in the GD group was significantly shorter than
that in the GND group before PSM (17.79 ± 18.65 days vs. 27.62 ± 21.71 days, P = 0.023). After PSM,
although there was no statistical significance, the GD group showed a shorter length of hospital stay
compared to that in the GND group. (16.33 ± 17.11 days vs. 25.05 ± 14.37 days, P = 0.082) (Table 3).
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Table 2. Clinical characteristics of patients in both groups before and after propensity score matching.
Variables
















Female, no. (%) 17(40.48) 19(38) 0.809 9(42.86) 8(38.10) 0.706
Age, years 61.02 ± 12.9 61.12 ± 14.62 0.974 61.38 ± 13.75 63.14 ± 14.35 0.714
Body mass index, kg/m2 24.59 ± 16.22 23.39 ± 3.39 0.656 26.24 ± 23.1 23.21 ± 2.84 0.557
Laboratory
White blood cell count per mm3 11,727.14 ± 10,485.66 16,539.4 ± 21,144.89 0.161 13,250.48 ± 10,956.11 13,380 ± 12,844.07 0.968
Hematocrit, % 34.08 ± 7.47 35.26 ± 8.62 0.489 33.95 ± 8.05 32.98 ± 7.55 0.696
Platelet per mm3 179,238.1 ± 131,796.19 185,660 ± 122,677.05 0.81 151,428.57 ± 87,436.59 189,380.95 ± 123,681.64 0.239
Blood urea nitrogen, mg/dL 32.35 ± 33.84 32.97 ± 18.04 0.915 34.18 ± 39.22 30.75 ± 17.1 0.725
Creatinine, mg/dL 2.05 ± 2.43 2.46 ± 2.44 0.421 2.4 ± 3.19 2.38 ± 2.89 0.981
Total bilirubin, mg/dL 0.91 ± 0.76 1.22 ± 1.33 0.168 0.97 ± 0.91 0.86 ± 0.53 0.642
Albumin, g/dL 3.19 ± 0.72 3.17 ± 0.78 0.93 3.11 ± 0.72 3.27 ± 0.65 0.419
C-reactive protein, mg/L 118.5 ± 87.18 152.78 ± 127.66 0.138 127.84 ± 93.94 167.4 ± 152.37 0.339
Lactate, mmol/L 3.3 ± 2.41 4.9 ± 4.18 0.029 3.23 ± 2.08 3.04 ± 1.96 0.576
Comorbidity
Congestive heart failure, no. (%) 0(0) 6(12) 0.03 0(0) 0(0) NA
Hypertension, no. (%) 23(54.76) 27(54) 0.942 12(57.14) 13(61.90) 0.739
Pulmonary disease, no. (%) 4(9.52) 3(6) 0.698 2(9.52) 0(0) NA
Liver disease, no. (%) 3(7.14) 3(6) >0.999 1(4.76) 1(4.76) >0.999
Diabetes mellitus, no. (%) 11(26.19) 15(30) 0.686 5(23.81) 6(28.57) 0.706
Renal disease, no. (%) 5(11.9) 8(16) 0.574 3(14.29) 3(14.29) >0.999
Cancer, no. (%) 18(42.86) 20(40) 0.782 9(42.86) 9(42.86) >0.999
Risk factor for MRSA, no. (%) 27(64.29) 25(50) 0.169 11(52.38) 11(52.38) >0.999
Initial SOFA score 7.95 ± 2.37 9.36 ± 3.17 0.02 8.05 ± 2.20 9.14 ± 3.73 0.169
Admission to ICU from ED, no. (%) 24(57.14) 34(68) 0.283 13(61.90) 13(61.90) >0.999
SOFA score at day 5 3.5 ± 3.62 4.7 ± 4.67 0.178 3.33 ± 3.5 3.71 ± 4.6 0.527
Primary focus of sepsis 0.801 0.609
Primary sepsis, no. (%) 9(21.43) 10(20) 3(14.29) 6(28.57)
Pneumonia, no. (%) 16(38.10) 16(32) 6(28.57) 4(19.05)
Intra-abdominal, no. (%) 10(23.81) 12(24) 9(42.86) 4(19.05)
Skin and soft tissue, no. (%) 2(4.76) 6(12) 1(4.76) 4(19.05)
Others a, no. (%) 5(11.9) 6(12) 2(9.52) 3(14.29)
MRSA, methicillin-resistant Staphylococcus aureus; SOFA, sequential organ failure assessment; ICU, intensive care unit; ED, emergency department. a Others include central nervous system
infections, gastroenteritis, deep neck infection, and others.
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Table 3. Comparison of clinical outcomes between groups before and after propensity score matching.
Outcomes


















OR 95% CI p-Value
New AKI, no. (%) 4.16 1.49–11.6 0.007 5.54 1.49–20.6 0.011
None 38(90.1) 37(74) 20(95.2) 16(76.2)
1-Creatinine ≥1.3 mg/dL
or
≥ 1.5 times than baseline
0(0) 4(8.16) 0(0) 1(5)
2-≥ 2 times than baseline 2(4.76) 1(2.04) 1(4.76) 0(0)
3-≥ 3 times than baseline 1(2.38) 1(2.04) 0(0) 0(0)
Hemodialysis needed 1(2.38) 6(12.24) 0(0) 3(15)
7-day mortality, no. (%) 1(2.38) 1(2) 0.84 0.05–13.8 0.901 1(4.76) 1(4.76) 1 0.06–15.99 >0.999
14-day mortality, no. (%) 2(4.76) 6(12) 2.73 0.52–14.29 0.235 1(4.76) 1(4.76) 1 0.06–15.99 >0.999
28-day mortality, no. (%) 4(9.52) 10(20) 2.38 0.69–8.22 0.172 2(9.52) 4(19.05) 2 0.37–10.92 0.427
Outcomes






















Hospital day 17.79 ± 18.65 27.62 ± 21.71 9.834 4.264 0.023 16.33 ± 17.11 25.05 ± 14.37 8.714 4.876 0.082
AKI, acute kidney injury; OR, odds ratio; CI, confidence interval.
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3. Discussion
In this propensity-matched retrospective cohort study, we demonstrated the outcomes of GD in
patients with culture negative severe sepsis or septic shock Although PSM was performed with a small
number of variables, the differences in baseline characteristics were not observed between the GD and
GND groups after PSM. Mortality at 7, 14, and 28-days did not increase in patients in the GD group
compared with those in the GND group. GND was associated with development of AKI, particularly
in patients who underwent hemodialysis.
Proper management of patients with sepsis requires not only rapid recognition of the bacterial
infection and administration of empirical broad-spectrum antibiotics, but also identification of the
suspected causative bacteria. Furthermore, there is need to switch to narrow spectrum antibiotics
based on the susceptibility results, and discontinuation of antibiotic therapy is important after use for
an appropriate duration [1]. As rapid recognition and prompt antibiotic use should be guaranteed in
patients with sepsis, many of them receive broad-spectrum antibiotics as the initial therapy more than
necessary. When the clinical specimen culture results become available in patients with sepsis, empirical
glycopeptides can be de-escalated or discontinued if MRSA is not identified [4]. Some physicians
continue glycopeptides in patients when signs of infection persist even after negative culture results
are identified. Our study showed that this practice did not improve clinical outcomes in patients;
rather, it increased the development of AKI. The proportion of vancomycin used in this study was
40% and 31.5% in the GD group and the GND group, respectively (data not shown). The duration of
vancomycin use is well known as one of the important determinants of vancomycin-induced renal
toxicity [10]. The longer duration of glycopeptide use, including vancomycin, in the GND group may
have contributed to the development of AKI. In addition, the higher incidence of AKI seems to serve as
one of the reasons for the longer hospital stay in the GND group, although not statistically significant.
Similar results were observed in another study, in which GD did not increase the mortality but reduced
the incidence of AKI and total hospital length of stay in patients with culture negative nosocomial
pneumonia [9].
This study did not include six cases of urinary tract infection in culture negative patients who
received glycopeptides as initial antibiotics. There are limited data to recommend the empirical use of
glycopeptides for treatment of urinary tract infection since MRSA is uncommon pathogen in urinary
tract infection [11]. Looney and colleagues reported that a very low proportion of all urine samples
tested were methicillin-resistant [12]. Our institution also does not recommend the use of glycopeptides
for treatment of urinary tract infection, even in severe sepsis or septic shock, unless the causative strain
is identified as MRSA. Therefore, we excluded cases of urinary tract infection that received initial
empiric glycopeptides.
Variable selection is important for the study using the PSM. However, there is lack of consensus to
determine which variables should be included in PSM. It is recommended to include as many variables
as possible. However, since a small number of patients were included in this study, we performed the
PSM using three variables (lactate, SOFA score on day 5, and congestive heart failure) that seemed to
have the greatest influence on the decision of GD and mortality. Lactate is a well-known biomarker
that can discriminate patients who are likely to die from those who are likely to live [1,13], and we
previously showed that the lactate level was an independent prognostic factor in our cohort patients
with severe sepsis and septic shock [14]. SOFA score at the time of the GD, day 5, in this study, would
be more important than SOFA score at admission, and initial SOFA score was not likely to affect
the physician’s decision for GD. Physicians tend to maintain the use of initial empirical antibiotics
if the severity of the patients’ condition does not improve, regardless of the culture results. In fact,
the mortality rate was significantly associated with the severity score on the day of available culture
results for severe sepsis or septic shock in studies of antibiotics DE [5,15]. We were able to clearly
demonstrate the impact of GD by adjusting the SOFA score at the time of GD. Although there was
a difference in the initial SOFA score at admission between the GD and GND groups, the difference
disappeared after PSM. Congestive heart failure was the only underlying comorbidity, in which a
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significantly different proportion was observed between the two groups. Furthermore, sepsis accounts
for a large proportion, almost a quarter, of death in patients with congestive heart failure [16]. Therefore,
we selected the lactate level, SOFA score on day 5, and congestive heart failure as the three variables
for propensity matching. Our previous study showed that pneumonia and intra-abdominal infection
had the highest mortality rates [14]. Although we did not include these variables in the PSM, there
were no differences between the GD and GND groups before and after the PSM.
Few studies evaluated the impact of antibiotic DE in only culture negative patients with severe
infections [9,17]. Antibiotic DE according to the identified pathogens and susceptibilities can improve
the outcome of patients [3,18]. Therefore, antibiotic DE is easily performed if pathogens are identified
in culture results [19]. We demonstrated that GD was safe and effective even if causative pathogens
were not identified. To the best of our knowledge, our study included the largest number of culture
negative severe sepsis or septic shock patients to evaluate the impact of GD. These findings can help
clinicians implement antibiotic DE in patients with culture negative severe sepsis or septic shock.
Our study has several limitations. First, since a small number of patients were included in this
study, the results should be cautiously interpreted because there were remaining potential bias and
confounding factors that could affect the outcomes. In addition, although significant differences were
not noted between the two groups after the PSM, we did perform PSM with a few variables due to the
limited patient number. Further studies are warranted with a larger patient size. Second, this study
was performed in a single center. Our institution’s large cohort consisted of adequate patients with
severe sepsis or septic shock to represent this population in other hospitals in South Korea. However,
the results observed in this study may not be applicable to other countries. Finally, there is a lack of
data regarding the incidence of drug resistant organisms or Clostridium difficile infection after treatment.
Excessive use of antibiotics causes a selection of those pathogens [20]. Because of the small sample
size and short duration of observation, it was not suitable to confirm the occurrence of antibiotic
resistant organisms.
4. Materials and Methods
4.1. Study Design and Population
A retrospective cohort study was performed at Severance Hospital (Seoul, South Korea), a 2400-bed
tertiary teaching hospital at Yonsei University College of Medicine. A sepsis critical pathway program
has been implemented in this institution to recognize patients with sepsis early and to begin prompt
treatment. When adult patients (age ≥18 years) with suspected or proven infection visited the
emergency department, those who had two or more systemic inflammatory response syndrome
criteria and one of hypotension or high lactate level (≥4 mmol/L), previously defined as severe sepsis
and/or septic shock, were included in the program [21,22]. The clinical management consisted of fluid
resuscitation for tissue perfusion, empirical broad-spectrum antibiotic therapy, and vasopressor use in
patients who remained hypotensive despite fluid resuscitation.
We analyzed the electronic medical records of patients registered in the sepsis critical pathway
program from January 2010 to March 2018. Patients who received glycopeptides as initial empirical
antibiotics were eligible for inclusion. Subsequently, we screened patients with no identified causative
pathogen in the final culture results. In addition, we considered patients with nonpathogenic colonizers
or normal flora in the culture results as having no identified causative pathogen. All patients were
included in this study only for the first episode. The following cases were excluded in this study:
(1) transfers to another hospital or hopeless discharge from hospital within 28 days after admission;
(2) death within 7 days after initial culture; (3) identification of causative pathogen in the follow
up culture; (4) glycopeptide use again within 7 days after discontinuation; (5) infections that may
require continued anti-MRSA treatment, such as infective endocarditis, endovascular graft infection,
mycotic aneurysm, device-related infection, and osteoarticular infection; (6) hospital acquired infection
transferred from another hospital; and (7) urinary tract infection.
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Patients were classified into two groups, the GD group and the glycopeptide non-discontinuation
(GND) group. GD group was defined as the group in which initial empiric glycopeptides were
discontinued when culture results became available and revealed the absence of identified pathogens.
The opposite cases were defined as the GND group. Glycopeptides were designated antibiotics in the
antimicrobial stewardship program at the hospital and were targets of preauthorization throughout
the study period [23].
This study was approved by the institutional review board of the Yonsei University Health System
Clinical Trials Center, and the protocol adhered to the tenets of the Declaration of Helsinki. Since the
study was retrospective and the study participants were anonymized, the institutional review board
waived the requirement for written consent from the patients.
4.2. Data Collection and Definition
Medical records of all patients were reviewed by one trained researcher and one infectious
disease specialist. Data for baseline characteristics, laboratory results, radiologic findings, treatments,
and outcomes were obtained from electronic medical records. Patients’ underlying comorbidities were
defined using the International Classification of Diseases, 10th revision. Acute kidney injury (AKI)
was identified according to the Kidney Disease: Improving Global Outcomes definition [24]. AKI was
classified as stage 1, 2, and 3 as follows: (1) Stage 1, increase in serum creatinine ≥1.3 mg/dL or ≥
1.5 times than baseline; (2) Stage 2, increase of ≥ 2 times than baseline; and (3) Stage 3, increase of
≥ 3 times than baseline. If the AKI progressed and hemodialysis was performed due to AKI, it was
defined as “Hemodialysis needed”. Patients with underlying end stage renal disease were excluded
from the evaluation of AKI development. The sequential organ failure assessment (SOFA) score was
used to assess the severity in patients with severe sepsis or septic shock at admission. Since the
severity of illness appeared to change during hospitalization, we re-evaluated the SOFA score on day 5,
when the culture results were almost confirmed, to reassess the severity. The primary focus of sepsis
was defined according to the Centers for Disease Control and Prevention/National Healthcare Safety
Network surveillance criteria [25]. Patients who satisfied one or more of the following conditions
were considered to have an MRSA risk factor: more than 2 days of hospitalization within the previous
90 days; living in a nursing facility; receipt of hemodialysis; infection with human immunodeficiency
virus; receipt of antibiotic therapy for more than 3 days within 30 days; and intravenous drug use.
4.3. Statistical Analysis
Categorical variables were expressed as numbers and percentages and were compared using
Chi-square tests. Continuous variables were expressed as median and interquartile range (IQR) and
were compared using the independent t-test (normal distribution) or Mann–Whitney test (non-normal
distribution). To adjust the effects of potential confounding factors between the GD and GND subjects,
a propensity score matching (PSM) analysis was used. Considering the total number of patients
expected to be included in our study and to avoid overfitting in the matching, propensity scores were
calculated through logistic regression model based on the following clinically selected factors: lactate
level, SOFA score on day 5, and congestive heart failure. PSM was performed using the SAS macro.
We used conditional logistic regression to compare the AKI and mortality between the GD and GND
groups in the matched data. Comparison of length of hospital stay between groups, linear mixed
model was performed in the matched data. Statistical analyses were performed using SAS version 9.4
(SAS Institute Inc., Cary, NC, USA).
5. Conclusions
Antibiotic DE can be one of the management strategies to avoid an increase in the mortality
rate in patients with sepsis, while reducing adverse drug events and preventing antibiotic resistance.
This study suggests that GD may be a reasonable option for management of patients with culture
negative severe sepsis or septic shock. Further studies with large sample size are needed to support
Antibiotics 2020, 9, 250 10 of 11
our results, and in terms of infection control, the effect of GD on preventing antibiotic resistance in
such settings should be analyzed.
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